TIGAR Antibody Announced by Novus Biologicals

Novus Biologicals announced today their new rabbit polyclonal antibody to TP53-induced glycolysis and apoptosis regulator, or TIGAR for short (catalog number NBP1-49534).

Novus' new TIGAR antibody is useful for Western blot and immunohistochemistry, and cross-reacts with human and mouse. The immunogen to which this TIGAR antibody was made is a genomic peptide made within residues 50-200 of the human TIGAR protein.

TIGAR is a protein with sequence similarity to the bisphosphate domain of the glycolytic enzyme that degrades fructose-2,6-bisphosphate. TIGAR functions by blocking glycolysis and directing the pathway into the pentose phosphate shunt. Expression of TIGAR also protects cells from DNA damaging reactive oxygen species and provides some protection from DNA damage-induced apoptosis.

Novus Biologicals provides a broad catalog of apoptosis antibodies, as well as p53 antibodies.  All products are 100% guaranteed to work in the species and applications listed on the datasheet, and the Innovator's Reward Program supports researchers testing of additional species and applications.

About Novus Biologicals (www.novusbio.com)

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science.  Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community.  All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet.  By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.


Release Date: 
Friday, January 21, 2011 - 07:00